Mieke Van Hemelrijck1, Xi Ji2, Jozien Helleman3, Monique J Roobol3, Wim van der Linden4, Daan Nieboer3, Chris H Bangma3, Mark Frydenberg5, Antti Rannikko6, Lui S Lee7, Vincent J Gnanapragasam8, Mike W Kattan2. 1. Translational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK. Electronic address: Mieke.vanhemelrijck@kcl.ac.uk. 2. Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA. 3. Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands. 4. Department of Professional Health Solutions & Services, Philips Research, Eindhoven, The Netherlands. 5. Department of Surgery, Monash University, Melbourne, Australia; Department of Urology, Monash Health, Melbourne, Australia. 6. Helsinki University and Helsinki University Hospital, Helsinki, Finland. 7. Department of Urology, Singapore General Hospital, Singapore. 8. Academic Urology Group, Department of Surgery and Oncology, University of Cambridge, Cambridge, UK.
Abstract
BACKGROUND: Careful assessment of the reasons for discontinuation of active surveillance (AS) is required for men with prostate cancer (PCa). OBJECTIVE: Using Movember's Global Action Plan Prostate Cancer Active Surveillance initiative (GAP3) database, we report on reasons for AS discontinuation. DESIGN, SETTING, AND PARTICIPANTS: We compared data from 10296 men on AS from 21 centres across 12 countries. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cumulative incidence methods were used to estimate the cumulative incidence rates of AS discontinuation. RESULTS AND LIMITATIONS: During 5-yr follow-up, 27.5% (95% confidence interval [CI]: 26.4-28.6%) men showed signs of disease progression, 12.8% (95% CI: 12.0-13.6%) converted to active treatment without evidence of progression, 1.7% (95% CI: 1.5-2.0%) continued to watchful waiting, and 1.7% (95% CI: 1.4-2.1%) died from other causes. Of the 7049 men who remained on AS, 2339 had follow-up for >5yr, 4561 had follow-up for <5yr, and 149 were lost to follow-up. Cumulative incidence of progression was 27.5% (95% CI: 26.4-28.6%) at 5yr and 38.2% (95% CI: 36.7-39.9%) at 10yr. A limitation is that not all centres were included due to limited information on the reason for discontinuation and limited follow-up. CONCLUSIONS: Our descriptive analyses of current AS practices worldwide showed that 43.6% of men drop out of AS during 5-yr follow-up, mainly due to signs of disease progression. Improvements in selection tools for AS are thus needed to correctly allocate men with PCa to AS, which will also reduce discontinuation due to conversion to active treatment without evidence of disease progression. PATIENT SUMMARY: Our assessment of a worldwide database of men with prostate cancer (PCa) on active surveillance (AS) shows that 43.6% drop out of AS within 5yr, mainly due to signs of disease progression. Better tools are needed to select and monitor men with PCa as part of AS.
BACKGROUND: Careful assessment of the reasons for discontinuation of active surveillance (AS) is required for men with prostate cancer (PCa). OBJECTIVE: Using Movember's Global Action Plan Prostate Cancer Active Surveillance initiative (GAP3) database, we report on reasons for AS discontinuation. DESIGN, SETTING, AND PARTICIPANTS: We compared data from 10296 men on AS from 21 centres across 12 countries. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cumulative incidence methods were used to estimate the cumulative incidence rates of AS discontinuation. RESULTS AND LIMITATIONS: During 5-yr follow-up, 27.5% (95% confidence interval [CI]: 26.4-28.6%) men showed signs of disease progression, 12.8% (95% CI: 12.0-13.6%) converted to active treatment without evidence of progression, 1.7% (95% CI: 1.5-2.0%) continued to watchful waiting, and 1.7% (95% CI: 1.4-2.1%) died from other causes. Of the 7049 men who remained on AS, 2339 had follow-up for >5yr, 4561 had follow-up for <5yr, and 149 were lost to follow-up. Cumulative incidence of progression was 27.5% (95% CI: 26.4-28.6%) at 5yr and 38.2% (95% CI: 36.7-39.9%) at 10yr. A limitation is that not all centres were included due to limited information on the reason for discontinuation and limited follow-up. CONCLUSIONS: Our descriptive analyses of current AS practices worldwide showed that 43.6% of men drop out of AS during 5-yr follow-up, mainly due to signs of disease progression. Improvements in selection tools for AS are thus needed to correctly allocate men with PCa to AS, which will also reduce discontinuation due to conversion to active treatment without evidence of disease progression. PATIENT SUMMARY: Our assessment of a worldwide database of men with prostate cancer (PCa) on active surveillance (AS) shows that 43.6% drop out of AS within 5yr, mainly due to signs of disease progression. Better tools are needed to select and monitor men with PCa as part of AS.
Authors: Gregory T Chesnut; Emily A Vertosick; Nicole Benfante; Daniel D Sjoberg; Jonathan Fainberg; Taehyoung Lee; James Eastham; Vincent Laudone; Peter Scardino; Karim Touijer; Andrew Vickers; Behfar Ehdaie Journal: Eur Urol Date: 2019-12-23 Impact factor: 20.096
Authors: Peter S Kirk; Kehao Zhu; Yingye Zheng; Lisa F Newcomb; Jeannette M Schenk; James D Brooks; Peter R Carroll; Atreya Dash; William J Ellis; Christopher P Filson; Martin E Gleave; Michael Liss; Frances Martin; Jesse K McKenney; Todd M Morgan; Peter S Nelson; Ian M Thompson; Andrew A Wagner; Daniel W Lin; John L Gore Journal: Cancer Date: 2021-09-13 Impact factor: 6.860
Authors: Lauren Folgosa Cooley; Adaeze A Emeka; Travis J Meyers; Phillip R Cooper; Daniel W Lin; Antonio Finelli; James A Eastham; Christopher J Logothetis; Leonard S Marks; Danny Vesprini; S Larry Goldenberg; Celestia S Higano; Christian P Pavlovich; June M Chan; Todd M Morgan; Eric A Klein; Daniel A Barocas; Stacy Loeb; Brian T Helfand; Denise M Scholtens; John S Witte; William J Catalona Journal: J Urol Date: 2021-09-10 Impact factor: 7.600
Authors: Daniël F Osses; Christian Arsov; Lars Schimmöller; Ivo G Schoots; Geert J L H van Leenders; Irene Esposito; Sebastiaan Remmers; Peter Albers; Monique J Roobol Journal: J Pers Med Date: 2020-12-10
Authors: Julia Wade; Jenny Donovan; Athene Lane; Michael Davis; Eleanor Walsh; David Neal; Emma Turner; Richard Martin; Chris Metcalfe; Tim Peters; Freddie Hamdy; Roger Kockelbergh; James Catto; Alan Paul; Peter Holding; Derek Rosario; Howard Kynaston; Edward Rowe; Owen Hughes; Prasad Bollina; David Gillatt; Alan Doherty; Vincent J Gnanapragasam; Edgar Paez Journal: BMJ Open Date: 2020-09-09 Impact factor: 2.692
Authors: Michelle M Kouspou; Jenna E Fong; Nadine Brew; Sarah T F Hsiao; Seanna L Davidson; Peter L Choyke; Tony Crispino; Suneil Jain; Guido W Jenster; Beatrice S Knudsen; Jeremy L Millar; Nicole Mittmann; Charles J Ryan; Bertrand Tombal; Mark Buzza Journal: Nat Rev Urol Date: 2020-07-22 Impact factor: 14.432